From the Guidelines
The recommended dosing regimen for Mounjaro (tirzepatide) in patients with type 2 diabetes in Canada is 15 mg weekly, as indicated by the pharmacokinetics data 1. To minimize gastrointestinal side effects, the initial dose is typically lower, but the provided evidence does not specify the exact initial dosing regimen. However, based on the information available, the total dose range for Mounjaro is up to 15 mg weekly, with a bioavailability of 1250 ng/ml after a single dose and an elimination half-life of 5 days 1. Some key points to consider when administering Mounjaro include:
- Administration route: subcutaneous (SC) injection
- Pharmacokinetics: suitable for once-weekly dosing due to its long elimination half-life
- Total dose range: up to 15 mg weekly for maximum efficacy
- Bioavailability: 1250 ng/ml after a single dose
- Elimination half-life: 5 days, allowing for once-weekly dosing
- Major elimination route: metabolized
- Active metabolite: no It is essential to note that while the provided evidence does not specify the initial dosing regimen, the recommended maximum dose of 15 mg weekly is clear, and dose adjustments may be necessary for patients with renal impairment or gastrointestinal disease, although specific guidance on these adjustments is not provided in the given evidence 1.
From the FDA Drug Label
2 DOSAGE AND ADMINISTRATION
2.1 Dosage The recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly. Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions (5.6) and Adverse Reactions (6.1)]. The 2. 5 mg dosage is for treatment initiation and is not intended for glycemic control. After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly. If additional glycemic control is needed, increase the dosage in 2. 5 mg increments after at least 4 weeks on the current dose. The maximum dosage of MOUNJARO is 15 mg injected subcutaneously once weekly.
The recommended dosing regimen for Mounjaro (tirzepatide) in patients with type 2 diabetes in Canada is as follows:
- Starting dose: 2.5 mg injected subcutaneously once weekly
- Dosage escalation: Increase the dosage to 5 mg after 4 weeks, and then in 2.5 mg increments every 4 weeks as needed for glycemic control
- Maximum dose: 15 mg injected subcutaneously once weekly 2
From the Research
Mounjaro Dosing in Canada
- The recommended dosing regimen for Mounjaro (tirzepatide) in patients with type 2 diabetes in Canada is not explicitly stated in the provided studies.
- However, according to the study 3, tirzepatide is administered at a dose of 5-15 mg per week, and has been shown to reduce HbA1c and body weight in patients with type 2 diabetes.
- The study 4 also reports that tirzepatide was administered at doses of 5,10, and 15 mg per week, and was found to be effective in improving glycemic control and reducing body weight.
Administration and Dosing
- The exact dosing regimen for Mounjaro in Canada may depend on various factors, including the patient's medical history, current medications, and response to treatment.
- It is essential to consult the product monograph or a healthcare professional for specific guidance on the use of Mounjaro in Canada, as the dosing regimen may vary depending on the individual patient's needs 5, 6.
Safety and Efficacy
- The studies 3, 4 report that tirzepatide has a safety profile consistent with GLP-1 receptor agonists, with common adverse events including nausea, diarrhea, and vomiting.
- Tirzepatide has been shown to be effective in improving glycemic control and reducing body weight, with significant reductions in HbA1c and body weight observed in clinical trials 3, 4.